Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-05-03
2005-05-03
Chen, Shin-Lin (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S267000, C435S320100, C435S455000, C424S093200, C424S093210
Reexamination Certificate
active
06887856
ABSTRACT:
A method of protecting a subject against an agent that elicits production of toxic free radicals, superoxide anions, or heavy metal cations in the subject is disclosed which entails in vivo administration to the subject of a polynucleotide encoding a protein that is transiently expressed in said subject. The transiently expressed protein is capable of neutralizing or eliminating the toxic free radicals, superoxide anions or heavy metal cations that are elicited by the agent. The method is particularly useful in protecting cancer patients against the damaging effects of ionizing radiation and chemotherapeutic drugs. A composition useful in carrying out the method also is disclosed.
REFERENCES:
patent: 4751180 (1988-06-01), Cousens et al.
patent: 4980286 (1990-12-01), Morgan et al.
patent: 5240847 (1993-08-01), Heckl et al.
patent: 5334383 (1994-08-01), Morrow
patent: 5599712 (1997-02-01), Greenberger
patent: 5670488 (1997-09-01), Gregory et al.
patent: 6221848 (2001-04-01), Greenberger
patent: 0284105 (1988-03-01), None
patent: 9312756 (1993-07-01), None
patent: WO 9419493 (1994-09-01), None
patent: WO 9421283 (1994-09-01), None
Ishiye et al., Oct. 15, 1992, FEMS Microbiology Letters, vol. 97, p. 235-241.*
Branch et al., 1993, American Review of Respiratory Disease, vol. 147, No. 4, Supp. S, pp. A206.*
Nabel et al., 1994, Annals New York Academy of Sciences, vol. 714, p. 247-252.*
Eck et al.; Gene-Based Therapy, 1996, The Pharmacological Basis of Therapeutics:77-101.*
Deonarain; Ligand-targeted receptor-mediated vectors for gene delivery, 1998, Exp. Opin. Ther. Patents 8:53-69.*
Verma et al.; Gene therapy- promises, problems and prospects, 1997, Nature, vol. 389: 239-242.*
Mastrangelo et sl., Seminars in Oncology vol. 23(1), p. 4-21, Feb. 1996.*
Orkin et al., Report and Recommendatioins of the Panel to Assess the NIH Investment in Research on Gene Therapy, Dec. 1995.*
Alton et al., Nature Genetics, 5:135-142, 1993.*
Hockenberry et al., Cell, 75:241-251, 1993.*
Jaffe et al., Nature Genetics, 1:372-378, 1992.*
Jolly, Cancer Gene Therapy, 1(1):51-64, 1994.*
Mulligan, Science, 260:926-932, 1993.*
Petkau, Cancer Treatment Rev., 13:17-44, 1986.*
Sorrentino et al., Science, 257:99-103, 1992.*
Wu et al., J. Biol. Chem., 263 14621-14624, 1988.*
Ledley, F.D., Human Gene Therapy, 2:77-83 (1991).*
Ledley, F.D., Current Opinion in Biotechnology, 5:626-636, 1994.*
Lehrer et al., Carcinogenesis 10(12):2279-84, 1989.*
Matsubara J. et al., Pharmac. Ther., 39:331-333, 1988.*
Marshall, Science, 269, 1995, 1050-1055.*
“NIH Report and Recommendations”, Dec. 7, 1995, 1-40.*
Xiang, K., “Multiple Taq I RFLPs at the Human Manganese Superoxide Dismutase (S0D2) locus on Chromosome 6”,Nucleic Acids Research, vol. 15, No. 18 (1987).
Hyland, V. J. et al., “A 5′ Flanking Region of the Metallothionein, MT2A, Gene Identifies Two Moderately Frequent RFLPs”,Nucleic Acids Research, vol. 15, No. 3 (1987).
Karin, M. et al., “Human Metallothionein Genes-Primary Structure of the Metallothionein-II Gene and a Related Processed Gene”,Nature, vol. 299 (Oct. 28 1982).
Sherman, L. et al., “Nucleotide Sequence and Expression of Human Chromosome 21-encoded Superoxide Dismutase mRNA”,Proc. Natl. Acad. Sci. USA, vol. 80, pp 5465-5469 (Sep. 1983).
Richards, R. I. et al., “Structural and Functional Analysis of the Human Metallothionein-IAGene: Differential Induction by Metal Ions and Glucocorticoids”,Cell, vol. 37, pp 263-272 (May 1984).
Lieman-Hurwitz, J. et al., “Human Cytoplasmic Superoxide Dismutase cDNA Clone: A Probe for Studying the Molecular Biology of Down Syndrome”, Proc. Natl. Acad. Sci. USA, vol. 79, pp 2808-2811 (May 1982).
Cai, D. W. et al., “Stable Expression of the Wild-Type p53 Gene in Human Lung Cancer Cells After Retrovirus-Mediated Gene Transfer”, Proceedings of the American Association of Cancer Research, vol. 34, p 505, 3011 (Mar. 1993).
McCormick, M. L. et al., “Superoxide Dismutase and Catalase Levels During Estrogen-Induced Renal Tumorigenesis, in Renal Tumors and their Autonomous Variants in the Syrian Hamster”,Carcinogenesis, vol. 12, No. 6, pp 977-983 (1991).
Engelhardt, J. et al., “In Vivo Retroviral Gene Transfer into Human Bronchial Epithelia of Xenografts”, The American Society for Clinical Investigation, Inc., vol. 90, pp 2598-2609 (Dec. 1992).
Oberley, L. W. et al., “Transfection of Manganese Superoxide Dismutase cDNA into Cultured Tumor Cells,”Proc. Amer. Assoc. for Canc. Res., Abstract 98 (1993).
Yang, Y. et al., “An Approach for Treating the Hepatobillary Disease of Cystic Fibrosis by Somatic Gene Transfer”,Proc. Natl. Acad. Sci. USA, vol. 90, pp 4601-4605 (May 1993).
Rosenfeld, M. A. et al., “Adenovirus-Mediated Transfer of a Recombinant α1-Antitrypsin Gene to the Lung Epithelium in Vivo”,Reports, pp 431-434 (Apr. 19, 1991).
Dunn, M. A. et al., “MINIREVIEW—Metallothionein (42525A)”, Proceedings of the Society for Experimental Biology and Medicine 185, pp 107-119 (1987).
Lohrer, H. et al., “Overexpression of Metallothionein in CHO Cells and its Effect on Cell Killing by Ionizing Radiation and Alkylating Agents”,Carcinogenesis, vol. 10, No. 12, pp 2279-2284 (1969).
Holland, C. et al., “Enhancer Sequences of a Retroviral Vector Determine Expression of a Gene in Multi-potent Hematopoietic Progenitors and Committed Erythroid Cells”,Proc. Natl. Acad. Sci. USA, vol. 84, pp 8662-8666 (Dec. 1987).
Roth, J. et al., “p53 Regulates the Transcription of Human Cytokeratin β Gene in Human Lung Cancer Cell Lines”, Proceedings of The American Association for Cancer Research, vol. 34, p 509 (Mar. 1993).
Petkau, A., “Scientific Basis for the Clinical Use of Superoxide Dismutase”,Cancer Treatment Reviews 13, pp 17-44 (1986).
Fujiwara, T. et al., “Retroviral-Mediated Transduction of p53 Gene Regulates TGF-β Gene Expression and Secretion in a Human Glioblastoma Cell Line”, Proceedings of the American Association for Cancer Research, vol. 34, p 449, 2680 (Mar. 1993).
Georges, R. N. et al., “In-Vivo Retroviral Transduction of Antisense K-ras Suppresses Tumor Growth in an Orthotopic Lung Cancer Model”, Proceedings of the American Association for Cancer Research, vol. 34, p 336 (Mar. 1993).
Shiraishi, N. et al., “Elevation in Metallothionein Messenger RNA in Rat Tissues After Exposure to X-Irradiation”,Toxicology and Applied Pharmacology 98, pp 501-506 (1989).
Flotte, T. et al., “Gene Expression from Adeno-Associated Virus Vectors in Airway Epithelial Cells”,Am. J. Respir. Cell Molec. Biol, 7:349 (1992).
Anklesaria, P. et al., “Engraftment of a Clonal Bone Marrow Stromal Cell Line in vivo Stimulates Hemato-poietic Recovery from Total Body Irradiation”,Proc. Natl. Acad. Sci. USA, vol. 84, pp 7681-7685, (Nov. 1987).
Armstrong, J. G. et al., “Three Dimensional Conformal Radiation Therapy May Improve the Therapeutic Ratio of High Dose Radiation Therapy for Lung Cancer”,Int. J. Radiation Oncology Biol. Phys., vol. 00, pp 001-005 (1993).
Georges, R. N. et al., “Prevention of Orthotopic Human Lung Cancer Growth by Intratracheal Instillation of a Retroviral Antisense K-ras Construct”,Cancer Research 53, pp 1743-1746 (Apr. 15, 1993).
Stribling, R., “Aerosol Gene Delivery in vivo”, Proc. Natl. Acad. Sci. USA, vol. 89, pp 11277-11281, (Dec. 1992).
Ferkol, T. et al., “Regulation of the Phosphoenolpyruvate Carboxykinase/human Factor IX Gene Introduced into the Livers of Adult Rats by Receptor-Mediated Gene Transfer”, Methodology, vol. 7, pp 1081-1091, (Aug. 1993).
Rosenfeld, M. et al., “In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene”, Cell, vol. 68 (Jan. 10, 1992).
Mulligan, R., “The Basic Sciences of Gene Therapy”,Science, vol. 260, pp 926-932 (May 14, 1993)
Chen Shin-Lin
Foley & Lardner LLP
University of Pittsburgh
LandOfFree
Protection from ionizing irradiation or chemotherapeutic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Protection from ionizing irradiation or chemotherapeutic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protection from ionizing irradiation or chemotherapeutic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3445296